Brief: NanoViricides Reports Excellent Safety Profile Of Its First Drug Candidate In Dermal Treatment Study
05/03/2019 12:14
March 5 (Reuters) - NanoViricides Inc NNVC.A :
* NANOVIRICIDES REPORTS EXCELLENT SAFETY PROFILE OF ITS
FIRST DRUG
CANDIDATE IN DERMAL TREATMENT STUDY
* NANOVIRICIDES INC - FIRST DRUG CANDIDATE HAS SUCCESSFULLY
COMPLETED FIRST OF SAFETY/TOXICOLOGY STUDIES MOVING TOWARDS
HUMAN CLINICAL TRIALS
Source text for Eikon: ID:nPnzvtGqa
Further company coverage: NNVC.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NanoViricides,
See all newsExplainer: What do we know about the Bundibugyo strain of the Ebola virus?
Brief: anoViricides Signs Agreement for Orphan Drug Strategy of NV-387 for Mpox, Smallpox, and Measles
Brief: Nanoviricides Says NV-387 Shows Activity Against Measles Virus In Humanized Animal Model
Brief: Nanoviricides Co's Business Not Affected By Tariff Policies Of Us Government Or Corresponding Retaliatory Policies Of Other Governments
Brief: Nanoviricides Obtained Right Of First Refusal For All Antiviral Drug Developments